<DOC>
	<DOCNO>NCT00997685</DOCNO>
	<brief_summary>This single arm , open-label phase II study evaluate efficacy safety Capecitabine plus oxaliplatin ( XELOX ) peri-operative treatment patient potentially resectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Evaluate Efficacy Safety XELOX Potentially Resectable Liver Metastasis From Colorectal Cancer ( CRC )</brief_title>
	<detailed_description>To investigate progression free survival ( PFS ) advantage Xeloda plus oxaliplatin peri-operative treatment potential resectable metastatic colorectal cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age 18 65 Histologically confirm colorectal cancer two methords image detection confirm liver metastasis Potentially curable resection , determine surgeon hepatic surgery expertise No evidence extrahepatic disease chest xray CT scan chest , abdomen , pelvis Patients adequate hepative , renal bone marrow function Signed write informed consent Pregnant nursing patient ( fertile patient must use effective contraception ) Other malignancy within past 5 year except completely resect nonmelanoma skin cancer carcinoma situ cervix Preexisting grade 2 great peripheral neuropathy Concurrent uncontrolled illness Ongoing active infection Psychiatric illness social situation would preclude study compliance Less 6 month since prior adjuvant fluorouracilbased chemotherapy Prior chemotherapy liver metastasis Prior oxaliplatin colorectal cancer Prior concurrent hepatic artery infusion chemotherapy metastatic disease Prior concurrent radiotherapy metastatic disease Prior concurrent radiofrequency ablation metastatic disease concurrent treatment anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>XELOX</keyword>
	<keyword>potentially resectable liver metastasis CRC</keyword>
</DOC>